Clinical Trial

Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2025 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years or more.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-24.
Trial Details
NCT Number NCT06954818
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions Herpes Zoster
Enrollment 200 participants
Start Date 2025-05-10
Primary Completion 2025-12-10 (estimated)
Study Completion 2026-11-10 (estimated)
Updated on ClinicalTrials.gov 2025-05-08